Application of Simultaneous Integrated Boost Intensity Modulated Radiotherapy in Locally Advanced Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2019.11.03
- Author:
Jing YOU
1
;
Dan YANG
1
;
Dongming LI
1
;
Leilei JIANG
1
;
Rong YU
1
;
Huiming YU
1
;
Bo XU
1
;
Weihu WANG
1
;
Anhui SHI
1
Author Information
1. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing 100142, China.
- Publication Type:Journal Article
- Keywords:
Efficacy;
Lung neoplasms;
Simultaneous integrate boost
- From:
Chinese Journal of Lung Cancer
2019;22(11):696-701
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:The standard treatment for locally advanced non-small cell lung cancer (NSCLC) is radiotherapy concurrent with chemotherapy, but the survival was not satisfied. With the development of intensity modulated radiotherapy, simultaneous integrated boost technique (SIB) becomes the research direction of locally advanced NSCLC. The aim of this study is to investigate the efficacy and safety of SIB intensity modulated radiotherapy technique for locally advanced NSCLC.
METHODS:We retrospectively reviewed the clinical data of locally advanced NSCLC who were treated with radiotherapy by SIB technique in Peking University Cancer Hospital from June 2015 to December 2018. Kaplan-Meier method was used for analysis.
RESULTS:Ninty-three patients were included in the analysis. After a median follow-up of 34.23 months, 3-year overall survival (OS), progression-free survival (PFS), local-recurrence free survival (LRFS) and metastasis free survival (MFS) rates were 53.0%, 37.0%, 50.5% and 50.5%, respectively. The incidence of grade ≥3 esophagitis was 5.4%. There were 2 (2.2%) patients experiencing grade ≥3 radiation-related pneumonia.
CONCLUSIONS:Radiation with SIB intensity modulated radiotherapy technique is effective and safe for patients with locally advanced NSCLC.
